ClinicalTrials.gg
RecruitingNCT061216223DPanNETUpdated May 1, 2025

Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours

An observational study in Pancreatic Neuroendocrine Tumor, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Adenoma, Islet Cell with a site in Italy — 3 open to participants now, 6 under way, 1 of them phase 3. Adenoma, Islet Cell · Italy.

Started
2024
with 1 other
Observational
6 of 11
1 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
IRCCS San Raffaele

Among the 11 studies in Adenoma, Islet Cell with a site in Italy, this one is one of 2 that started in 2024, is one of 6 observational ones, and was the 8th registered.

Adenoma, Islet Cell

113 studies on the registry are indexed under Adenoma, Islet Cell; 30 are open to participants now.

Browse Adenoma, Islet Cell studies →

Open to participants now

3 of the 11 studies in Adenoma, Islet Cell with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 24 Adenoma, Islet Cell studies recruiting now, 17 (71%) set no upper age limit and 2 (8%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Adenoma, Islet Cell with a site in Italy, or all of them as a file.
02

Study summary

The goal of this prospective observational study is to generate new personalised 3D preclinical models of pancreatic neuroendocrine tumors. The models will be exploited for studying the mechanisms underlying disease development and progression, as well as for performing drug testing. For the development of the newly proposed models, patients' surgical specimens will be evaluated by the Pathological Unit. If the presence of pathological material in excess, not required for the routine diagnostic procedure, is confirmed, such material will be employed for the generation of the proposed personalised models.

Read the detailed description

Pancreatic neuroendocrine tumors (PanNETs) are characterized by highly heterogeneous biological behavior. Another distinctive feature of these neoplasms is the presence of a dense vascular network, reminiscent of their physiological counterpart. Indeed, the tumor microenvironment plays a critical role in these neoplasms and influence their therapeutic management. Although they are typically indolent in nature, approximately 40% of PanNET patients are metastatic at diagnosis, requiring non-surgical treatments such as somatostatin therapy, chemotherapy, targeted therapy, and peptide receptor radionuclide therapy (PRRT). Furthermore, 1 out of 5 patients experience disease recurrence after surgical resection, necessitating pharmacological therapies. Currently, no specific recommendations exist on the most effective therapeutic sequence to follow in presence of metastatic disease/disease relapse. One of the main reasons behind this unmet clinical need is the scarcity of available preclinical models of these neoplasms able to accurately reproduce the biology and physiology of the primary tumor and that can be used as valid platforms for drug testing.

The study aims to generate a new 3D in vitro model of PanNET, replicating the complex primary tumor in vitro, including also the tumor microenvironment (e.g., vascular network and stroma, essential elements of these neoplasms), personalised for each patient. Indeed, for the development of the newly proposed models, patients' surgical specimens will be initially evaluated by the Pathological Unit and, in the presence of pathological material in excess not required for the routine diagnostic procedure, it will be employed for the generation of the proposed personalised models. 3D culture techniques (e.g., 3D bioprinting) will be used for the development of the models. Moreover, in order to further mimic in vitro the in vivo environment, the models will be maintained under dynamic conditions.

These newly proposed models will be exploited for studying the mechanisms underlying disease development and progression, as well as for performing drug testing.

03

Conditions studied

  • Pancreatic Neuroendocrine Tumor

Browse trials for

Keywords

  • PanNET
  • 3D preclinical models
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total number of approximately 70 patients will be enrolled

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients who undergo pancreatic surgical resection for non-functioning pancreatic neuroendocrine tumor
  • age ≥ 18 years

Exclusion criteria

Exclusion criteria:

  • non-pancreatic neuroendocrine tumor histological diagnosis
  • age \< 18 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours

    Generation of new 3D preclinical models of pancreatic neuroendocrine tumors for the study of the disease biology and for the assessment of drug response

    Time frame: from the day of surgery until 3 years from surgery

07

Study locations

1 of 1 sites recruiting
  • IRCCS San Raffele Institute
    Milan, MI 20132, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Nov 2029, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Nov 8, 2023
StartActual
Jan 16, 2024
Primary completionEst.
Nov 2029
CompletionEst.
Dec 2029
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06121622
Lead sponsor
IRCCS San Raffaele
Responsible party
Anna Battistella (Principal Investigator, IRCCS San Raffaele) — Principal investigator
First posted
Nov 8, 2023
Start date
Jan 16, 2024
Primary completion
Nov 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
May 1, 2025

Study contacts

Massimo Falconi, Professor
Contact
falconi.massimo@hsr.it
0039 022643 6046
Anna Battistella, MD
Contact
battistella.anna1@hsr.it
0039 02 26433484

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion